29.65
+0.17%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Energenesis Biomedical Co
Its shares trade on Taiwan Stock Exchange under the ticker 6657.TW. It has been listed since 8 August 2018. In the fiscal year to 31 December 2025, it reported revenue of TWD 7.7m and a net loss of TWD 258.4m. At that date it held total assets of TWD 949.0m and shareholders' equity of TWD 896.3m.
Energenesis Biomedical Co., Ltd. engages in the development of new drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-08-08. The firm's main product projects include experimental service analysis and reagent sales. The firm's main new drugs include ENERGI-F703, ENERGI-F701, ENERGI-F711, and ENERGI-F706. The ENERGI-F703 indications are diabetic foot ulcers. The ENERGI-F701 indications are abnormal alopecia. The ENERGI-F711 indications are burns. The ENERGI-F706 indications are cachexia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Aug 2018
- Website
- energenesis-biomedical.com ↗
Leadership
Pay as last reported
- Mr. Han-Min ChenChairman of the Board, since 2016TWD 14.3m
- Jin-Hua HuangVice Chairman of the Board, since 2025
- Mr. Ming-Tsan ChiangSenior Deputy General Manager-General Administrative DivisionTWD 2.9m
- Jiafu ChenDeputy General Manager
- Mr. Jiun-tsai LinSenior Deputy General Manager-IP DivisionTWD 4.0m
- Ms. Pei-chao ChenHead of Finance & Accounting
- Mr. Chung-Jung TsaiDirectorTWD 246,000
- Mr. Wei-Chyun WengDirector
- Mr. Ke-Hua DingIndependent DirectorTWD 786,000
- Mr. Shou-Shan WuIndependent DirectorTWD 783,000
- Mr. Yu-Ren WuIndependent DirectorTWD 783,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Energenesis Biomedical's ENERGI-F703 targets diabetic foot ulcers with innovative drug development.
- The company's ENERGI-F701 addresses abnormal alopecia through advanced biotechnology solutions.
- Energenesis Biomedical's ENERGI-F711 focuses on burn treatment with specialized reagent sales.
Weaknesses
- The company's ENERGI-F706 is in development for cachexia treatment without current market presence.
- Energenesis Biomedical lacks a diversified product portfolio beyond four main drug projects.
- The firm's experimental service analysis remains limited to internal research applications.
Opportunities
- Expanding ENERGI-F703 into diabetic foot ulcer markets in Taiwan and Asia could increase revenue streams.
- Growing demand for burn treatments in Asia presents a significant opportunity for ENERGI-F711.
- The biotechnology sector in Taiwan offers potential for new drug development partnerships.
Threats
- Competition from established biotech firms in Taiwan may impact ENERGI-F703's market share.
- Regulatory challenges in Taiwan could delay the approval of new drugs like ENERGI-F701.
- Economic downturns in Asia might reduce investment in biotechnology research and development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.